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Abstract
We aimed to establish that a bronchoscopic view can be as reliable as microbiology, and support an empirical tracheobronchial fungal
infection (TBFI) treatment decision. We retrospectively studied 95 respiratory failure patients with suspected TBFI admitted to the
intensive-care unit (ICU) in 2008 with sticky secretions, hyperaemic mucosa, and whitish plaques on bronchoscopic view. Patients not
suspected of having TBFI were chosen as a control group (n = 151). Broncheoalveolar lavage (BAL) ﬂuid was cultured, and biopsy samples
were taken from the lesions. Biopsy samples positive for fungi were deﬁned as ‘proven’, only BAL-positive (+ fungi) cases were ‘probable
TBFI’, and BAL-negative (– fungi) cases were ‘possible TBFI’. BAL (+ fungi) and BAL (– fungi) in the control group were deﬁned as
‘colonization’ and ‘no TBFI’, respectively. The sensitivity, speciﬁcity and positive and negative predictive values of BAL (+ fungi) were 85.1%
(63/74), 81.4% (140/172), 66.3% (63/95), and 92.7% (140/151), respectively. Biopsies were performed in 78 of 95 patients, and 28 were
proven TBFI with fungal elements, and 100% were BAL (+ fungi). Probable TBFI was seen in 30 of 95 patients with BAL (+ fungi), and
possible TBFI (BAL(– fungi)) in 25 of 95. Among the 95 patients, microbiology revealed fungi (90.5% Candida species; 9.5% Aspergillus) in 63
(66.3%). In the controls, the colonization and no TBFI rates were 11 of 151 and 140 of 151, respectively. Observing sticky secretions,
hyperaemic mucosa and whitish plaques by bronchoscopy is faster than and may be as reliable as microbiology for diagnosing TBFI. These
ﬁndings are relevant for empirical antifungal therapy in suspected TBFI patients in the ICU.
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Introduction
Flexible bronchoscopy (FB) is an extremely crucial method in
the intensive-care unit (ICU) and an important diagnostic
tool for the pulmonologist [1,2]. Endobronchial lesions can
be observed and diagnostic specimens, lavage and brush
materials can be easily obtained by FB [3]. Accordingly, FB
has a considerable place in the management of tracheobron-
chial fungal infections (TBFIs). However, the diagnosis of TBFI
by microbiology and pathology analysis takes 2–3 days at a
minimum. Combined with the high rate of colonization [4],
this means that, particularly in mechanically ventilated
patients [5], a rational therapeutic approach may be delayed
or obscured. Only a few studies have documented fungal
disease in critically ill, non-neutropenic patients [4,6,7]. To
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the best of our knowledge, no one has yet assessed the value
of the bronchoscopic inspection in TBFIs to provide clues for
rational antifungal treatment. In our respiratory ICU, patients
in whom we observed sticky secretions accompanied by
hyperaemic and irregular mucosa, followed by whitish
plaques and subsequent nodules, were frequently conﬁrmed
by microbiology and histopathology to have TBFI. It is
already known that fungal disease may manifest as mucosal
plaques in infants, older adults who wear dentures, patients
being treated with antibiotics, chemotherapy, or radiation
therapy, and those with cellular immunodeﬁciency [8–11].
Recently, bronchoscopy TBFI ﬁndings in immunocompro-
mised patients were summarized in a review [12]. We
hypothesized that patients with these bronchoscopic ﬁndings
could alert us to suspect TBFI in critically ill patients in the
ICU.
In this study, which is the ﬁrst and the largest of its kind, we
evaluated the detection of whitish plaques by bronchoscopic
examination of the tracheobronchial tree, relative to the
clinical and laboratory data, in non-neutropenic ICU patients
with acute respiratory failure (ARF), to provide evidence for
empirical antifungal treatment.
Materials and Methods
This retrospective, observational, case–control study was
conducted in the respiratory ICU of Sureyyapasa Chest
Diseases and Thoracic Surgery Training and Research Hospital,
Istanbul, Turkey. Our unit is labelled as a level III ICU, and has
a 20-bed capacity. The criterion for inclusion of patients in the
study was clinical suspicion of TBFI [12] during FB in a patient
with ARF [13]. The study was carried out between 1 January
and 31 December 2008. All invasive procedures, including FB,
were performed as a result of clinical indications, and all
patients provided signed informed consent. We obtained
hospital approval from the Institutional Review Board for this
study.
FB (Olympus)
FB was performed for aspiration of secretions and for
diagnostic analyses in eligible intubated patients. The nasal
route was used for observing the upper level of the vocal
cords in all non-intubated patients.
The bronchoscopic view for suspected TBFI
TBFI was suspected when whitish, sticky secretions, oedema-
tous hyperaemic mucosa and/or mucosal plaque formation
were observed. When TBFI was suspected, a bronchial
mucosal biopsy was performed in all eligible cases.
Modiﬁed deﬁnitions of TBFI
We prepared a ﬂow chart (Fig. 1) for deﬁnitions of ‘proven’,
‘probable’ and ‘possible’ TBFIs, and ‘colonization’ or ‘no TBFI’,
with the aid of guidelines [5]. Proven TBFI: in the case of
suspected TBFI, tissue biopsy and tracheobronchial washing
reveal fungi. Probable TBFI: in the case of suspected TBFI, the
pathology ﬁndings are negative, but the microbiology results of
tracheobronchial washing reveal fungi. Possible TBFI: TBFI is
suspected, but pathology and microbiology ﬁndings are
negative for fungi. Colonization: tracheobronchial washing
reveals fungi without bronchoscopic suspicion of TBFI. No
TBFI: patients have no bronchoscopic ﬁndings of TBFI, and
have negative histology or microbiology ﬁndings for fungi.
Data collection
Patient demographics, APACHE II scores [14] on admission to
the ICU, reasons for ARF [13], pneumonia [1,2], chronic
obstructive pulmonary disease exacerbation, infections follow-
ing thoracic surgery, chronic parenchymal diseases, pre-ICU
locations, mechanical ventilation, day of bronchoscopic sam-
pling, length of pre-ICU stay, tracheostomy, diabetes mellitus,
steroid use, tracheal complications and laboratory data were
recorded.
Pathology
Biopsy samples were examined after staining with Grocot and
periodic acid–Schiff reagent. TBFI was characterized by
disintegration of the surface epithelium, acute inﬂammatory
cell inﬁltration and ﬁbrin in the bronchial and tracheal mucosa,
and yeast-like pseudohyphae among the necrotic cells [15,16].
The type of fungus was not determined. Patients were further
separated into two groups according to whether the histopa-
thology ﬁndings were positive or negative for fungi.
Microbiology
Bronchial and tracheal washings were cultured onto Sabou-
raud’s dextrose agar, and a microbiological culture analyser
(mini API; Biomerieux, Marcy l’Etoile, France) was used for
mould and yeast identiﬁcation. Candida was classiﬁed into
albicans and non-albicans; further differentiation of Candida
could not be performed, owing to inadequate laboratory
resources. Aspergillus was identiﬁed by inoculating bronchial
and tracheal washings onto Sabouraud’s dextrose agar;
colonies that were fast-growing and white, yellow, yellow–
brown, brown to black or green in colour were accepted as
positive.
Bacterial cultures were quantiﬁed and microorganisms with
>104 CFUs/mL were assessed as indicative of an infection
requiring bronchial washing. Urine, blood, tracheal aspirate
and other examples were also examined when needed.
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Antifungal therapy was initiated according to the national
guidelines for non-neutropenic patients, in the form of
intravenous ﬂuconazole (10 mg/kg twice daily as a loading
dose for the ﬁrst day, and subsequently 10 mg/kg once daily as
a maintenance dose) or classical amphotericin B (0.5–1 mg/kg
intravenously as a single dose per day) as the ﬁrst choice
before culture results were available. If Aspergillus was iden-
tiﬁed, treatment was switched to voriconazole (6 mg/kg twice
daily for the ﬁrst day as a loading dose, and subsequently 4 mg/
kg once daily as a maintenance dose). If renal or liver function
test abnormalities, or allergic reactions, were detected, or
culture results were obtained, caspofungin (70 mg per day
intravenously as a loading dose, and a maintenance dose of
50 mg/day) or liposomal amphotericin B (5 mg/kg intrave-
nously as a single dose per day) were substituted. In the case of
patients with plaque formation, the duration of treatment was
4–8 weeks, depending on observations of changes in the
plaques. When there was no plaque formation, the duration of
treatment was 2–4 weeks, and in those patients with candi-
daemia the duration of treatment was 14 days, or until the
ﬁnal blood culture was negative for fungi.
Statistical analysis
Descriptive analyses were used for the evaluation of the data,
with SPSS statistical software (SPSS version 15.0; SPSS,
Chicago, IL, USA). Data were expressed as median, interquar-
tile range (25–75%), and percentage (%), where appropriate.
The Mann–Whitney U-test was used for non-parametric data,
and the chi-square test was used for dichotomous variables. A
p-value of <0.05 was assumed to be signiﬁcant.
Results
During the study period, 634 patients were admitted to our
respiratory ICU, and 246 underwent bronchoscopy for various
reasons. TBFI was suspected in 95 patients (case group), and
the other 151 patients were accepted as the control group.
The demographic data and ICU outcomes of all of the study
subjects are summarized in Table 1. Both groups were similar
with respect to demographics, comorbidities, APACHE II
score on admission to the ICU, and mortality rates. However,
the case group had a higher rate and longer duration of
invasive mechanical ventilation than the control group. The
length of stay in the ICU was signiﬁcantly greater in the case
group.
Fungal cultures of BAL ﬂuids were positive in 74 patients
(30.1%). In the case group (n = 95), 63 patients (66.3%) had
a positive fungal culture; in the control group (n = 151), 11
patients (7.3%) had a positive fungal culture. The sensitivity,
speciﬁcity and positive and negative predictive values of the
bronchoscopic view of TBFI as compared with BAL ﬂuid
results were as follows: 85.1% (63/74), 81.4% (140/172),
66.3% (63/95), and 92.7% (140/151), respectively. Among
the 95 case patients, the microbiology results of 63 (66.3%)
revealed fungi (90.5% Candida species; 9.5% Aspergillus).
Biopsies were performed in 78 patients; the other 17
patients refused the biopsy. Bronchoscopy was performed
in 32 of the 95 case patients via the nasal route, and eight of
these patients had plaque formations on the vocal cords.
Four of these cases were intubated after bronchoscopy, as
they were unresponsive to non-invasive mechanical venti-
lation. The remaining patients had bronchoscopy via an
endotracheal tube. Histopathology revealed fungi in 28
(35.9%) patients; 50 (64.1%) showed no fungi. Patients
deﬁned as TBFI ‘proven’, ‘probable’, ‘possible’, ‘coloniza-
tion’ and ‘no TBFI’ according to the bronchoscopic view,
BAL ﬂuid culture and histopathology are summarized in
Fig. 2.
Bronchoscopy was performed in the ﬁrst 3 days of ICU
admission in the majority of patients (73.3%). The median time
to bronchoscopy in the ICU was 2 days (interquartile range:
Bronchoscopy findings such as:
• Whitish, sticky secretions, oedematous hyperaemic mucosa, and/or mucosal plaque formation on
vocal cord, epiglottis and upper or lower part of tracheal mucosa 
No TBFI Suspected TBFI
Absent Present
Fungi present
Pathology for fungi
Positive for fungi
Proven TBFI Probable TBFI
Bronchial lavage culture for fungi
Negative for fungiFungi absent
Possible TBFI
Bronchial lavage culture for fungi
PositiveNegative
ColonizationNo TBFI FIG.1. Flow chart of suspected
tracheobronchial fungal infection (TBFI)
by bronchoscopy.
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1–4). Plaques were mostly seen at the tracheal mucosa next to
the vocal cords, at the distal part of the trachea, or at the
bilateral bronchial mucosa. Table 2 shows the relationship
between plaque formation and the laboratory data.
In the case group, empirical antifungal treatment was given
in 82 cases after observing typical TBFI, on the basis of the
patient’s clinical results. Antifungal treatment for suspected
TBFI, before any microbiology and histopathology results had
been acquired, was given to 26 of 28 proven TBFI patients, 31
of 42 probable TBFI patients, and 25 of 25 of possible TBFI
patients. In the control group, no patient received empirical
antifungal treatment. Two patients whose histology and BAL
culture results were positive for fungi did not receive
antifungal therapy, as these patients died before the decision
to initiate therapy could be made. Renal supplement dialysis
was not required for any of the patients while they were in the
ICU. Mortality rates in the ICU in the proven, probable and
possible TBFI cases were 28.6% (8/28), 21.4% (9/42), and
24.0% (6/25), respectively. In the control group, the mortality
rates in the ICU for patients with colonization and no TBFI
were 45.5% (5/11) and 24.3% (34/140), respectively. None of
the patients who died underwent an autopsy.
Discussion
In this study, we showed that endobronchial inﬂammatory
lesions detected by FB revealed that the majority of mucosal
plaques were related to invasive fungal disease in critically ill,
non-neutropenic patients. Although bacterial infections signif-
icantly contribute to mortality in the ICU, fungal diseases are
increasingly being seen in non-neutropenic, critical patients
[17,18]. In the EPIC-II study, which evaluated the prevalence
and outcomes of infections in the ICU, fungal isolates
constituted 21% of all positive blood cultures [19]. In another
study, as many as 5.5% of the ICU patients, in the absence of
neutropenia, had a conﬁrmed Candida infection [4]. Previously,
several authors have also reported the occurrence of invasive
pulmonary aspergillosis in COPD patients, with a very high
mortality rate [20–24].
On the whole, data related to TBFI in non-neutropenic
patients hospitalized in the ICU are lacking. In the present
study, histopathology showed yeast-like pseudohyphae among
the necrotic cells and the surface epithelium, acute inﬂamma-
tory cell inﬁltration, and ﬁbrin in the bronchial and tracheal
mucosa. Blood vessel invasion by fungi was not found in any of
our cases. In a review that evaluated the distribution of fungal
species in TBFI, Aspergillus species (53%) and Coccidioides
TABLE 1. Patient group demographics and intensive-care
unit (ICU) data of patients with suspected tracheobronchial
fungal infection (TBFI)
Suspected
TBFI: case
No TBFI
suspected:
control p-value
Number of patients 95 151
Demographic data
Age in years (range) 66 (56–72) 66 (56–76) 0.46
Gender, male/female 70/25 98/53 0.15
Comorbidities, n (%)
COPD 63 (66.3) 94 (62.3) 0.52
Diabetes 18 (18.9) 22 (14.6) 0.37
Cancer 12 (12.6) 19 (12.6) 0.99
ICU data
APACHE II score (range) 22 (17–27) 22 (17–26) 0.83
Reason for ARF, n (%)
Pneumonia 35 (36.8) 57 (37.7) 0.93
COPD exacerbation 58 (61.1) 89 (58.9)
Cardiogenic oedema 1 (1.1) 2 (2.0)
Restrictive lung disease 1 (1.1) 2 (1.3)
Mechanical ventilation
IMV, n (%) 63 (66.3) 79 (52.3) 0.030
IMV (days) (range) 8 (3–15) 4 (2–9) 0.009
NIMV, n (%) 65 (68.4) 109 (72.2) 0.53
NIMV (days) (range) 8 (4–10) 5 (2–10) 0.07
Tracheostomy, n (%) 21 (22.1) 25 (16.6) 0.28
Length of ICU stay in days (range) 11 (7–20) 8 (4–14) 0.007
ICU mortality, n (%) 22 (23.2) 39 (25.8) 0.64
ARF, acute respiratory failure; COPD, chronic pulmonary obstructive disease;
IMV, invasive mechanical ventilation; NIMV, non-invasive mechanical ventilation.
Bronchoscopy findings such as:
Whitish,sticky secretions, oedematous hyperaemic mucosa, and/or mucosal plaque formation on
vocal cords or/and epiglottis or/and upper or lower part of tracheal mucosa 
No TBFI N = 151 Suspected TBFI N = 95Absent Present
Fungi present
N = 28
Pathology for fungi
N = 78
BAL(+) N = 12
Proven TBFI N = 28 Probable TBFI N = 42
Bronchial lavage culture for fungi
N = 17
BAL(–) N = 5Fungi absent
N = 50
Possible TBFI N = 25
Bronchial lavage culture for fungi
N = 151
(+) N = 11(–) N = 140
ColonizationNo TBFI
Bronchoscopy in the Respiratory ICU, N = 246
BAL (–)
N = 20
BAL (+)
N = 30BAL (+)N = 28FIG. 2. The results of suspected
tracheobronchial fungal infection (TBFI)
by bronchoscopy. ICU, intensive-care unit.
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immitis (16%) were reported to be the most frequent. The
patients in this review were mostly immunocompromised, and
the percentage of Candida was very low (6%) [12]. In contrast,
in our study, the Candida isolates were responsible for 90.5%
of all TBFIs, whereas Aspergillus species were responsible for
only 9.5%. We were unable to subclassify the Candida isolates,
because of inadequate laboratory resources. When whitish
plaques were detected on bronchoscopic examination, TBFI
was conﬁrmed histopathologically in more than half of the
cases. Consequently, the detection of whitish plaques by FB
should alert the treating clinician to the presence of an invasive
fungal disease, according to our data.
In a prospective and post-mortem study performed in
critically ill and non-neutropenic patients, various factors, such
as antibiotic use, duration of antibiotic treatment, mechanical
ventilation period, age, acute respiratory distress syndrome,
parenteral nutrition, and gender, did not affect Candida
isolation from the lungs [25].
According to our data, antifungal treatment is strictly
indicated when whitish tracheobronchial plaques are detected
on bronchoscopic examination, as TBFI was conﬁrmed histo-
pathologically in a couple of days in more than half (54%) of the
cases. In this study, TBFIs caused by non-albicans types of
Candida constituted three-quarters of all biopsy-proven Can-
dida infections. Non-albicans Candida species are known to
have higher resistance to ﬂuconazole [26–28]. The treating
clinician should also bear in mind that an early start of rational
antifungals in invasive fungal disease has a profound impact on
mortality [6,29]. In the present study, we did not have
antifungal susceptibility test results.
Meersseman et al. [30] showed that, in 77 pneumonia
patients in whom tracheal lavage revealed Candida, no Candida
could be histologically detected post-mortem. No autopsies
were performed on our patients, and fungal pneumonia was
not evaluated with lung biopsy. Wood et al. [31] performed a
study in a level 1 trauma ICU, where they included 62 patients
whose BAL ﬂuid was positive for Candida. They suggested that
isolation of Candida from BAL ﬂuid in quantities below the
diagnostic threshold for ventilator-associated pneumonia in
this population does not require antifungal therapy. However,
we treated the majority of patients who were biopsy-negative,
because their clinical severity and bronchoscopic appearance
were identical to those of histologically proven cases.
Delisle et al. performed a study to investigate Candida
colonization and its associated risk factors, and to examine the
clinical outcomes, in patients with clinical suspicion of venti-
lator-associated pneumonia with concordant Candida coloni-
zation (n = 114) and without Candida colonization (n = 525)
[32]. They stated that it is unclear whether Candida coloniza-
tion is causally related to poor outcome, or whether it is a
marker for increased morbidity and mortality in the ICU.
The mortality rate in our patients with Candida colonization
was greater than in the respiratory tract Candida colonization
group of Delisle et al. (45.5% vs. 32.4%), and they also did not
treat these patients with antifungal drugs. The mortality rate of
patients with no TBFI was nearly similar to that of the TBFI
cases (proven, probable, and possible), and lower than that of
the Candida colonization group. The length of ICU stay in the
study of Delisle et al. was nearly seven times higher than in our
study (59.9 vs. 8 days).
Kontoyiannis et al. performed a study to evaluate the BAL
results for diagnosis of fungal infections [33]. Our study
showed the BAL results for diagnosis of TBFI were similar
according to sensitivity and negative predictive values (85.1%,
92.7% versus 85%, 93%, respectively) and higher in speciﬁcity
and positive predictive value when compared to the study
done by Kontoyiannis et al. (81.4%, 66.3% versus 60%, 42%
respectively) [33].
There are some limitations to our study. First, we could not
subclassify Candida species and perform antifungal susceptibility
tests, owing to inadequate laboratory resources. Moreover, we
did not perform post-mortem biopsies to further determine the
exact cause of death and to assess Candida invasion in other
tissues. Our data are from patients with ARF, the majority of
whom had chronic obstructive pulmonary disease and used
inhaler steroids, and for this reason our TBFI rates might be
higher, and our results should not be generalized for all patients.
In conclusion, in our study, cases of suspected TBFI
following a speciﬁc bronchoscopic view were nearly always
veriﬁed by a positive fungal culture in the tracheobronchial
lavage ﬂuids. In the presence of plaque in the airway mucosa,
the chance of a positive pathology ﬁnding for fungi appears to
be increased. Our results might be helpful to intensivists
TABLE 2. The relationship of plaque development and the
laboratory data of 95 patients with suspected tracheobron-
chial fungal infection (TBFI)
Variables
Plaque
(+), n = 56
Plaque
(–), n = 39 p-value
Fungi, n (%) (BAL ﬂuids)
Candida albicans 4 (7.1) 5 (12.8) 0.09
Candida non-albicans 25 (44.6) 17 (43.5)
Aspergillus spp. 6 (10.7) 0
Candida albicans + non-albicans 3 (5.4) 0
Isolation of pathogenic bacteria from
BAL ﬂuid, n (%)
Pseudomonas aeruginosa 10 (17.8) 7 (17.9) 0.30
Methicillin-resistant Staphylococcus
aureus
11(19.6) 4 (10.3)
Klebsiella pneumonia 5 (8.9) 4 (10.3)
Enterococci 18 (1.7) 1(2.7)
Acinetobacter baumannii 13 (23.2) 2 (5.1)
Escherichia coli 3 (5.4) 1(2.7)
Other enteric bacteria 2 (3.6) 3(7.8)
Isolation of multiple bacteria (>2) 32 (57.1) 18 (46.1) 0.29
Histopathology for fungi (+), n (%) 26/48 (54) 2/30 (6.7) 0.0001
BAL, bronchoalveolar lavage.
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attempting to diagnose and treat colonization or infection with
fungi in patients with ARF in the ICU when BAL ﬂuids are
positive for fungi. Thus, ICU patients, particularly those with
ARF, appear to have a greater chance of developing TBFI,
which can be easily detected by bronchoscopic examination. If
tracheobronchial plaques are detected by bronchoscopy, a
deﬁnite diagnostic approach and empirical therapy for fungi
should be seriously considered.
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